Compare NetEase Inc (NTES) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetEase Inc vs State Street SPDR S&P Biotech ETF — how do they compare? NetEase Inc trades at $124.76 (market cap $76.09B), while State Street SPDR S&P Biotech ETF trades at $154.06 (market cap $10.11B). The key difference: NetEase Inc is far larger — about 7.5× State Street SPDR S&P Biotech ETF's market cap, and NetEase Inc pays a 2.45% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold NetEase Inc for 74 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| NTES | XBI | |
|---|---|---|
Market Cap | $76.09B | $10.11B |
Volume | 486,447 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $152.85 | $169.55 |
52-Week Low | $109.26 | $104.99 |
Typical Hold Time | 74 Days | 37 Days |
Enterprise Value | $51.81B | — |
Dividend Yield | 2.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NetEase (NTES) trades at $120.61, up 1.29% with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $112.63B revenue and 27.88% net margin in 2025, though recent quarterly earnings show volatility with two misses in the last three quarters. Analyst consensus remains strongly bullish with 82% buy ratings and a $168 price target representing 39% upside potential.
The investment case balances strong profitability and cash generation against earnings volatility and competitive pressures. Key opportunities include consistent revenue growth and attractive valuation multiples, while risks center on gaming market competition and China regulatory environment. The stock presents value for long-term investors given the significant discount to analyst targets.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
